Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2023 May Pharma News Vyxeos liposomal now reimbursed in Belgium for patients with untreated high-risk AML Read more
2023 January Covid-19 Breakthrough COVID-19 in vaccinated patients with haematologic malignancies Read more
2022 November Clinical practice Long-term remission rates after treatment with tisagenlecleucel in paediatric and young adult ... Read more
Top
